J. Jukema

发表

Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation

H. Huikuri, H. Suryapranata, A. Bagai, 2024, European heart journal. Cardiovascular pharmacotherapy.

Alirocumab and cardiovascular outcomes according to sex and lipoprotein(a) after acute coronary syndrome: ODYSSEY OUTCOMES

R. Pordy, M. Scemama, J. Mcginniss, 2024, Journal of Clinical Lipidology.

Addressing residual risk beyond statin therapy: New targets in the management of dyslipidaemias-A report from the European Society of Cardiology Cardiovascular Round Table.

L. Tokgozoglu, J. Plat, N. Cater, 2024, Journal of clinical lipidology.

The impact of patient-reported frailty on cardiovascular outcomes in elderly patients after non-ST-acute coronary syndrome.

M. Stoel, M. Gimbel, C. Runnett, 2024, International journal of cardiology.